Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Abujamel, Turki ^a   Cadnum, Jennifer L ^b   Jury, Lucy A ^c   Sunkesula, Venkata C K ^d   Kundrapu, Sirisha ^d   Jump, Robin L ^c   Stintzi, Alain C ^a   Donskey, Curtis J ^c,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; RNA 16S; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIUM IDENTIFICATION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; FECES ANALYSIS; FEMALE; GROWTH INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROFLORA; MULTIDRUG RESISTANCE; RECURRENT DISEASE; RNA SEQUENCE; SEQUENCE ANALYSIS;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DRUG RESISTANCE, BACTERIAL; FECES; FEMALE; HUMANS; MALE; METRONIDAZOLE; MICROBIOTA; MIDDLE AGED; PROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84884823455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076269     Document Type: Article

References (26)

1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31: 431-455. doi:10.1086/651706. PubMed: 20307191.
2. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, et al. (2008) Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52: 2403-2406. doi:10.1128/AAC.00090-08. PubMed: 18443120.
3. Sethi AK, Al-Nassir WN, Nerandzic MM, Donskey CJ, (2009) Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 30: 13-17. doi:10.1086/592710. PubMed: 19046063.
4. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE, (1997) Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 25: 729-732. doi:10.1086/513755. PubMed: 9314469.
5. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M, (2009) OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 53: 261-263. doi:10.1128/AAC.01443-07. PubMed: 18955523.
6. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN, (2002) Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186: 1781-1789. doi:10.1086/345676. PubMed: 12447764.
7. Bolton RP, Culshaw MA, (1986) Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27: 1169-1172. doi:10.1136/gut.27.10.1169. PubMed: 3781329.
8. Nerandzic MM, Donskey CJ, (2009) Effective and reduced-cost modified selective medium for isolation of Clostridium difficile. J Clin Microbiol 47: 397-400. doi:10.1128/JCM.01591-08. PubMed: 19073869.
9. Bidet P, Lalande V, Salauze B, Burghoffer B, Avesani V, et al. (2000) Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 38: 2484-2487. PubMed: 10878030.
10. Terhes G, Urbán E, Sóki J, Hamid KA, Nagy E, (2004) Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 42: 4316-4318. doi:10.1128/JCM.42.9.4316-4318.2004. PubMed: 15365032.
11. Currie BP, Lemos-Filho L, (2004) Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci. Antimicrob Agents Chemother 48: 4427-4229. doi:10.1128/AAC.48.11.4427-4429.2004. PubMed: 15504873.
12. Rolfe RD, Finegold SM, (1983) Intestinal β-lactamase activity in ampicillin-induced, Clostridium difficile-associate ileocecitis. J Infect Dis 147: 227-235. doi:10.1093/infdis/147.2.227. PubMed: 6600772.
13. Borriello SP, Barclay FE, (1986) An in vitro model of colonization resistance to Clostridium difficile infection. J Med Microbiol 21: 299-309. doi:10.1099/00222615-21-4-299. PubMed: 3723582.
14. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, et al. (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338: 120-123. doi:10.1126/science.1224820. PubMed: 22903521.
15. Magoč T, Salzberg SL, (2011) FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27: 2957-2963. doi:10.1093/bioinformatics/btr507. PubMed: 21903629.
16. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, et al. (2011) Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A 108 (Suppl 1):: 4516-4522. doi:10.1073/pnas.1000080107. PubMed: 20534432.
17. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, et al. (2011) Metagenomic biomarker discovery and explanation. Genome Biol 12: R60. doi:10.1186/gb-2011-12-6-r60. PubMed: 21702898.
18. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, et al. (1992) Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 117: 297-302. doi:10.7326/0003-4819-117-4-297. PubMed: 1322075.
19. Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, et al. (2007) Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335: 80. doi:10.1136/bmj.39231.599815.55. PubMed: 17604300.
20. Malaguarnera G, Leggio F, Vacante M, Motta M, Giordano M, et al. (2012) Probiotics in the gastrointestinal diseases of the elderly. J Nutr Health Aging 16: 402-410. doi:10.1007/s12603-011-0357-1. PubMed: 22499466.
21. Dabard J, Bridonneau C, Phillipe C, Anglade P, Molle D, et al. (2001) Ruminococcin, new lantibiotic produced by a Ruminococcus gnavus strain isolated from human feces. Appl Environ Microbiol 67: 4111-4118. doi:10.1128/AEM.67.9.4111-4118.2001. PubMed: 11526013.
22. Lau SK, McNabb A, Woo GK, Hoang L, Fung AM, et al. (2007) Catabacter hongkongensis gen. nov., sp. nov., isolated from blood cultures of patients from Hong Kong and Canada. J Clin Microbiol 45: 395-401. doi:10.1128/JCM.01831-06. PubMed: 17122022.
23. Lau SK, Fan RY, Lo HW, Ng RH, Wong SS, et al. (2012) High mortality associated with Catabacter hongkongensis bacteremia. J Clin Microbiol 50: 2239-2243. doi:10.1128/JCM.00128-12. PubMed: 22518872.
24. Robinson CJ, Young VB, (2010) Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 1: 279-284. doi:10.4161/gmic.1.4.12614. PubMed: 20953272.
25. Sommer MO, Dantas G, (2011) Antibiotics and the resistant microbiome. Curr Opin Microbiol 14: 556-563. doi:10.1016/j.mib.2011.07.005. PubMed: 21802347.
26. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN, (2012) Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 56: 5224-5229. doi:10.1128/AAC.00913-12. PubMed: 22850511.